India's Natco Pharma rises on tentative US nod for cancer drug generic
20/07/2026 08:08
BUZZ-India's Natco Pharma rises on tentative US nod for cancer drug generic ** Drug maker Natco Pharma's shares NATP.NS rise as much as 4.5%, their sharpest intraday rise in two weeks, to 987.55 rupees apiece
** NATP last up 2.6%
** Rise after NATP receives tentative approval from the U.S. drug regulator for Olaparib, 100 mg and 150 mg, a bioequivalent to the reference listed drug (RLD) Lynparza tablets
** Olaparib, which is used to treat specific types of cancers, had estimated sales of $1.4 billion in the U.S for 12 months ending March 2026, NATP says in an exchange filing
** NATP shares are up 7.7% in 2026 so far, lagging the 15% rise in the pharma index .NIPHARM, exchange data shows
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees